Cell reports · 2026
NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chanvillard Lucie, Lantermans Hildo C, Wall Christopher, Thevenet Jonathan, Butter Loes M, Tauzin Loic, Claessen Nike, Christen Stefan, Holzwarth James A, Karaz Sonia, Lassueur Steve, Lizzo Giulia, Sanchez-Garcia José Luis, Métairon Sylviane, Ferro Valentina, Moco Sofia, van Bommel Erik J M, van Baar Michael J B, Hesp Anne C, van Raalte Daniel H, Roelofs Joris J T H, Neelakantan Harshini, Watowich Stanley J, Sanders Matthew J, Feige Jerome N, Sorrentino Vincenzo, Tammaro Alessandra
Аннотация
Chronic kidney disease (CKD) is projected to become the fifth leading cause of mortality by 2040. Tubular senescence drives kidney fibrosis, but current treatments do not target senescent cells. Here, we identify nicotinamide-N-methyltransferase (NNMT) as a critical mediator of tubular senescence and kidney fibrosis. Human CKD microarrays link NNMT to senescence and fibrosis transcriptomic signatures, and diabetic kidney disease (DKD) biopsies show NNMT protein associating with p21, fibrosis, and kidney function decline. Spatial transcriptomics in human biopsies demonstrates that NNMT-positive tubules are senescent, fibrotic, and surrounded by a pro-inflammatory microenvironment. Importantly, this pattern is conserved in aged and DKD mice, mimicking early-stage CKD features. Mechanistically, NNMT overexpression in tubular epithelial cells exacerbates senescence and partial epithelial-to-mesenchymal transition, while selective NNMT inhibition in senescent kidney cells, organoids, and in vivo is protective. Altogether, these findings position NNMT as a promising therapeutic target to reduce tubular senescence and fibrosis in early CKD.